Assess the efficacy of a thrombolytic agent in reducing infarct size and thereby improving ventricular function and subsequent morbidity and mortality. The primary endpoint will be total mortality during the follow up period. Secondary endpoints include determination of the: effect of thrombolytic therapy on left ventricular ejection fraction;proportion of patients suspected of having myocardial infarction with complete versus incomplete occlusion of the infarct related artery; time limits for successful reperfusion including differences according to the route of administration; and frequency and severity of adverse effects of intracoronary and intravenous administration of thrombolytic agents in patients with acute infarction.

Agency
National Institute of Health (NIH)
Institute
Division of Heart And Vascular Diseases (NHLBI)
Type
Research and Development Contracts (N01)
Project #
N01HV038030-003
Application #
3660103
Study Section
Project Start
1983-06-30
Project End
1986-08-31
Budget Start
1985-03-01
Budget End
1986-02-28
Support Year
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905